AFYX Therapeutics

Copenhagen, Capital Region, Denmark

Company profile

AFYX Therapeutics company profile

AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

Business identity

Website: https://afyxtx.com/
Contact email: [email protected]@afyxtx.com
Operating status: Active
Company type: For Profit
Employee range: 00001-00010 employees
Revenue range: $1K+
Founded: 2013-01-01

LinkedIn Facebook X

Headquarters

Headquarters: Copenhagen, Capital Region, Denmark
Postal code: 2300
Country code: DK
Continent: Europe

Capital profile

Funding and company signals

Funding stage: Early Stage Venture
Funding rounds: 3
Total equity funding: $17.6M
Last funding: Debt Financing / $13M / 2019-06-24
Last equity funding: Series A / $17.6M
Investors: 4
Lead investors: 3
Founders: 1
Articles: 8

Categories and groups

Biotechnology Clinical Trials Delivery Health Care Pharmaceutical Therapeutics Administrative Services Biotechnology Health Care Science and Engineering

Founders and investors

Founders

Jens Hansen

Lead investors

Lundbeckfonden EmergeNovo HoldingsSofinnova Investments

Investors

EISMEALundbeckfonden EmergeNovo HoldingsSofinnova Investments

People at this company

Preview only. Contact details are available after you sign in.

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Shipment records and coverage can change as the dataset is updated.